April 01, 2026 10:02 pm (IST)
Follow us:
FIR against Snapdeal CEO for selling prescription drugs online
Mumbai, May 1 (IBNS) Maharashtra's Food and Drugs Administration (FDA) has ordered that a First Information Report (FIR) be filed against Kunal Bahl, the CEO of e-commerce giant Snapdeal.com, for the sale of prescription drugs online.
FDA commissioner Harshadeep Kamble said on Friday said the FIR has been ordered against Bahl and directors of the company.
The FDA said it had received information about the alleged sale of a cough syrup, and certain tablets, both prescription drugs that can be sold only when prescribed by medical practitioner.
The FDA had issued a notice to the company asking it to delist the drugs and also furnish details of the drugs it offered for sale on the portal Snapdeal.com.
In a statement on Friday, Snapdeal said they are assisting in the probe and have delisted the products.
"In this matter, we are assisting the FDA team in this investigation and we will continue to do so. We have already delisted the products and said sellers and also stopped payment, in addition to providing all information to the FDA team as required by them," the statement said.
The FDA has said it is also checking to see if other e-retailers have sold drugs online.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow
Wed, Apr 01 2026
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed
Wed, Apr 01 2026